Brain Tumor in Pediatrics: Pediactric Glioblastoma: Review Article


Desyafitri Mutiarayani


Background: Glioblastoma (GBM) is a malignant brain tumor that can occur in children and is very aggressive which means it can grow and spread quickly. Approximately 16% of all primary brain and central nervous system neoplasms are glioblastomas. This makes GBM a major public health problem. The incidence of glioblastoma in children varies.glioblastoma Low-grade has a higher incidence in children aged 0 to 14 years, which is 1.8/100,000 while high-grade glioblastoma is 0.5/100,000 lower than low-grade glioblastoma. where the incidence rate of glial and neuroepithelial tumors is higher in children aged 0-14 years.

Content: Various factors such as genetic and environmental factors have been studied in terms of the etiology of glioblastoma. GBM develops more frequently in children with specific genetic syndromes, such as neurofibromatosis 1 (NF1), Li-Fraumeni syndrome, hereditary nonpolyposis colon cancer, and tuberous sclerosis. However, most cases of GBM have no known cause. Symptoms of glioblastoma are non-specific. The duration of symptoms is usually short and lasts for several months

Summary: In children, central nervous system tumors are the most common, with 3-15% being glioblastomas. Glioblastoma usually presents with non-specific symptoms and lasts a short duration of several months. In addition, the prognosis is also poor with high morbidity and mortality so that to improve the patient's quality of life, effective therapy is needed. Therapy can be in the form of surgery, radiotherapy, or chemotherapy.



1. Davis ME. Glioblastoma. HHS Public Access. 2016:20(5):1–14. Available from:
2. Rajaratnam V, Islam MM, Yang M, Slaby R, Ramirez HM, Mirza SP. Glioblastoma : Pathogenesis and Current Status of Cancers. 2020:12(937):1–28.
3. Hanif F, Muzaffar K, Perveen K, Malhi SM, Simjee S. Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical Presentation and Treatment. APJCP. 2017:18(1):3–9. Available from:
4. Strum D, et al. Pediatric Gliomas : Current Concepts On Diagnosis Biology, and Clinical Management. J. Clin. Oncol. 35, no. 21 (July 20, 2017): 2370-2377. doi :10.1200/JCO.2017.73.024
5. Maher EA, Bachoo RM. Glioblastoma, Rosenberg’s Molecular and Genetic Basis of Neurological and Psychiatric Disease: Fifth Edition. 2014. doi: 10.1016/B978-0-12-410529-4.00078-4.
6. Das KK, Kumar R. Pediatric Glioblastoma. In: De Vleeschouwer S, editor. Glioblastoma [Internet]. Brisbane (AU): Codon Publications; 2017 Sep 27. Chapter 15. Available from: doi: 10.15586/codon.glioblastoma.2017.ch15
7. Kanderi T, Gupta V. Glioblastoma Multiforme. 2021 Nov 20. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 32644380.
8. Olar A, Aldape KD. Using the molecular classification of glioblastoma to inform personalized treatment. J. Pathol. 2014:232(2):165–177. Available from:
9. Hasan I, Sekarutami SM. STANDAR PENGOBATAN GLIOBLASTOMA MULTIFORME. Journal of the Indonesian Radiation Oncology Society. 2014:5(2):51–60.
10. Packer RJ. Diagnosis and treatment of pediatric brain tumors. Current opinion in neurology. 1994:7(6):484–91.
11. Mahvash, M. Hugo HH, Maslehaty H, Mehdorn HM, Stark AM. Glioblastoma multiforme in children: report of 13 cases and review of the literature. Pediatric neurology. 2011:45(3): 178–80.
12. Adams H, Adams HHH, Jackson C, Rincon TJ, Jallo GI, Quiñones HA. Evaluating extent of resection in pediatric g lioblastoma: a multiple propensity score-adjusted population-based analysis. Childs Nerv Syst: official journal of the International Society for Pediatric Neurosurgery. 2016:32(3):493–503
13. Aibaidula A, Zhao W, Wu JS, Chen H, Shi ZF, Zheng LL, Mao Y, Zhou LF, Sui GD. Microfluidics for rapid detection of isocitrate dehydrogenase 1 mutation for intraoperative application. J. Neurosurg. 2016:124(6):1611–8.
14. Nikitović M, Stanić D, Pekmezović T, Gazibara MS, Bokun J, Paripović L, Grujičić D, Sarić M, Mišković I. Pediatric glioblastoma: a single institution experience.,” Childs Nerv Syst: official journal of the International Society for Pediatric Neurosurgery. 2016:32(1):97–103.
15. Mallick S, Gandhi AK, Joshi NP, Kumar A, Puri T, Sharma DN, Haresh KP, Gupta S, Julka PK, Rath GK, Sarkar C. Outcomes of pediatric glioblastoma treated with adjuvant chemoradiation with temozolomide and correlation with prognostic factors. Indian J. Med. Pediatr Oncol. 2016:36(2):99–104.
16. Manrique GS, Herrada PT, RF. Surgical Management of Glioblastoma. 2017.
17. Kline C, Felton E, Allen IE, Tahir P, Mueller S. Survival outcomes in pediatric recurrent high-grade glioma: results of a 20- year systematic review and meta-analysis. J. Neuro-Oncol. 2018:137(1):103–110.
18. El AM, Ansari M, Sturm D, Gielen GH, Warmuth MM, Kramm CM, Bueren AO. High-grade glioma in very young children: a rare and particular patient population. Oncotarget. 2017:8(38):64564–64578.
19. Durando X, Lemaire JJ, Tortochaux J, VP, Kwiatkowski F, Vincent C, Bailly C, Verrelle P, Irthum B, Chazal J, Bay JO. High-dose BCNU followed by autologous hematopoietic stem cell transplantation in supratentorial high-grade malignant gliomas: a retrospective analysis of 114 patients. Bone marrow transplantation. 2003:31(7):559–64.
20. Finlay JL, Boyett JM, Yates AJ, Wisoff JH, Milstein JM, Geyer JR, Bertolone SJ, McGuire P, Cherlow JM, Tefft M. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs- in-1-day regimen. Childrens Cancer Group. J. Clin. Oncol 1995:13(1):112–23.
21. Diwanji TP, Engelman A, Snider JW, Mohindra P. Epidemiology, diagnosis, and optimal management of glioma in adolescents and young adults.. Adolesc. Health, Med. Ther. 2017:8:99–113.